Skip to main content

Table 3 Clinicopathologic characteristics of patients according to breast cancer phenotype a

From: Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype

Parameters

Total

Luminal A

Luminal B

HER2

TNBC

P-value

(N= 740) (%)

(n= 298) (%)

(n= 166) (%)

(n= 69) (%)

(n= 207) (%)

Age (years, mean ± SD)

49.7 ± 11.0

50.6 ± 10.5

48.5 ± 10.1

52.8 ± 9.8

48.4 ± 12.4

0.007

Histologic grade

     

<0.001

 I

118 (15.9)

90 (30.2)

18 (10.8)

1 (1.4)

9 (4.3)

 

 II

373 (50.4)

180 (60.4)

90 (54.2)

35 (50.7)

68 (32.9)

 

 III

249 (33.6)

28 (9.4)

58 (34.9)

33 (47.8)

130 (62.8)

 

Tumor stage

     

0.002

 T1

358 (48.4)

166 (55.7)

86 (51.8)

31 (44.9)

75 (36.2)

 

 T2

367 (49.6)

125 (41.9)

78 (47.0)

37 (53.6)

127 (61.4)

 

 T3

15 (2.0)

7 (2.3)

2 (1.2)

1 (1.4)

5 (2.4)

 

Nodal stage

     

0.041

 N0

436 (58.9)

168 (56.4)

91 (54.8)

42 (60.9)

135 (65.2)

 

 N1

200 (27.0)

90 (30.2)

43 (25.9)

13 (18.8)

54 (26.1)

 

 N2

66 (8.9)

27 (9.1)

17 (18.5)

10 (14.5)

12 (5.8)

 

 N3

38 (5.1)

13 (4.4)

15 (9.0)

4 (5.8)

6 (2.9)

 

Estrogen receptor status

     

<0.001

 Negative

286 (38.6)

5 (1.7)

5 (3.0)

69 (100.0)

207 (100.0)

 

 Positive

454 (61.4)

293 (98.3)

161 (97.0)

0 (0.0)

0 (0.0)

 

Progesterone receptor status

     

<0.001

 Negative

371 (50.1)

50 (16.8)

46 (27.7)

69 (100.0)

207 (100.0)

 

 Positive

369 (49.9)

248 (83.2)

120 (72.3)

0 (0.0)

0 (0.0)

 

HER2 status

     

<0.001

 0

290 (39.2)

108 (36.2)

23 (13.9)

0 (0.0)

159 (76.8)

 

 1+

186 (25.1)

118 (39.6)

33 (20.0)

0 (0.0)

35 (16.9)

 

 2+

142 (19.2)

72 (24.2)

41 (24.7)

16 (23.2)

13 (6.3)

 

 3+

122 (16.5)

0 (0.0)

69 (41.6)

53 (76.8)

0 (0.0)

 

Ki-67 LI (%, mean ± SD)

18.1 ± 19.2

4.7 ± 3.7

19.7 ± 12.7

19.5 ± 12.5

35.6 ± 23.7

<0.001

Tumor recurrence

69 (9.3)

15 (5.0)

12 (7.2)

11 (15.9)

31 (15.0)

<0.001

Patient’s death

67 (9.1)

14 (4.7)

11 (6.6)

12 (17.4)

30 (14.5)

<0.001

Duration of clinical follow-up (months, mean ± SD)

70.2 ± 31.7

72.7 ± 30.0

70.3 ± 30.3

67.1 ± 35.8

67.8 ± 33.8

0.291

  1. aLI, labeling index; TNBC triple-negative breast cancer.